Success in anemia trials is measured as reduction in transfusion requirement, improvement in haemoglobin, or achievement of transfusion-independence. Response rates vary by anaemia subtype: aplastic anaemia and myelodysplastic syndrome report 40–60% transfusion-independence; chronic kidney disease anaemia reports 30–50% improved haemoglobin requiring reduced erythropoietin doses; autoimmune haemolytic anaemia reports 35–55% reduction in haemolytic markers. Younger patients and those with less advanced bone-marrow damage respond more favourably. Duration and intensity of prior immunosuppression influence baseline response potential. Overall, approximately 40% of anaemia patients show clinically meaningful improvement following MSC therapy.
Anemia trials represent the largest stem-cell research cohort, reflecting disease prevalence and unmet medical need. Trial outcomes vary substantially by anaemia type. In aplastic anaemia and myelodysplastic syndrome cohorts, MSC infusion has supported haematopoietic recovery, with some patients achieving transfusion-independence. In chronic kidney disease anaemia, paracrine effects of MSCs may enhance endogenous erythropoietin responsiveness. Autoimmune haemolytic anaemia trials report reduced haemolysis markers and improved haemoglobin in responsive patients. However, heterogeneous trial designs, small sample sizes, and variable control arms limit systematic comparison. Eighty-three recruiting trials suggest ongoing clinical momentum, though few have advanced to Phase 3 efficacy endpoints. Long-term haematological stability post-treatment remains incompletely characterised.
Am I a candidate? → · Anemia: full overview → · Anemia cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача